Article Details

EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and ...

Retrieved on: 2021-03-22 22:52:30

Tags for this article:

Click the tags to see associated articles and topics

EpimAb Biotherapeutics Raises $120M in Series C Financing to Advance Bispecific Programs and .... View article details on hiswai:

Excerpt

EpimAb Biotherapeutics, a clinical stage biotech company specializing in bispecific antibody ... with strong participation from existing investors such as Decheng Capital, SDIC Fund, Sherpa ... KEYWORD: CHINA ASIA PACIFIC.

Article found on: www.oaoa.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up